Aptorum Group Limited (NASDAQ:APM) Short Interest Down 24.8% in March

Aptorum Group Limited (NASDAQ:APM) was the recipient of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 8,693 shares, a decline of 24.8% from the February 26th total of 11,553 shares. Based on an average trading volume of 21,427 shares, the short-interest ratio is presently 0.4 days. Approximately 0.4% of the company’s shares are short sold.

Aptorum Group Price Performance

APM opened at $0.93 on Monday. The company has a fifty day simple moving average of $0.87 and a 200 day simple moving average of $1.26. Aptorum Group has a twelve month low of $0.65 and a twelve month high of $4.47.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Aptorum Group in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.